Previous Close | 3.9600 |
Open | 3.9800 |
Bid | 3.7000 x 800 |
Ask | 4.9200 x 800 |
Day's Range | 3.8220 - 4.0650 |
52 Week Range | 2.5200 - 14.5000 |
Volume | |
Avg. Volume | 793,587 |
Market Cap | 103.423M |
Beta (5Y Monthly) | 1.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.8820 |
Earnings Date | Feb 24, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following industry and scientific conferences in July:
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS), has been published in the peer reviewed journal, Annals of Clinical and Translational Neurology.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in June: